Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

HT-100

Small molecule · developed by Processa Pharmaceuticals

Phase 2 Most advanced trial (none active)
PCSA Developer
1 Registered trials

What is HT-100?

HT-100 is halofuginone hydrobromide in a delayed-release tablet formulation. It is studied in Duchenne muscular dystrophy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Musculoskeletal
Developer
Processa Pharmaceuticals (PCSA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
L31MM1385E

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01847573 Phase 1/2 Duchenne Muscular Dystrophy Terminated PCSA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Duchenne Muscular Dystrophy

More from Processa Pharmaceuticals

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PCSA page.

Follow PCSA, the company behind HT-100

See PCSA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PCSA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.